β-catenin programs a tissue-specific epigenetic vulnerability in aggressive adrenocortical carcinoma
Abstract
Adrenocortical carcinoma (ACC) is a rare cancer in which tissue-specific differentiation is paradoxically associated with dismal outcomes. The differentiated ACC subtype CIMP-high is prevalent, incurable, and routinely fatal. CIMP-high ACC possess abnormal DNA methylation and frequent β-catenin activating mutations. Here, we demonstrate that ACC differentiation is maintained by a balance between nuclear, tissue-specific β-catenin-containing complexes and the epigenome. On chromatin, β-catenin binds master adrenal transcription factor SF1 and hijacks the adrenocortical super-enhancer landscape to maintain differentiation. Off chromatin, β-catenin binds histone methyltransferase EZH2, which is redistributed by the CIMP-high DNA methylation signature. SF1/β-catenin and EZH2/β-catenin complexes exist in normal adrenals and are selected for through all phases of ACC evolution. Pharmacologic EZH2 inhibition in CIMP-high ACC favors EZH2/β-catenin assembly and purges SF1/β-catenin from chromatin, erasing differentiation and restraining cancer growth in vitro and in vivo. Our studies illustrate how tissue-specific programs shape oncogene selection, surreptitiously encoding targetable therapeutic vulnerabilities.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
↵21 Co-senior authors,
Subject Area
- Biochemistry (11573)
- Bioengineering (8623)
- Bioinformatics (28875)
- Biophysics (14805)
- Cancer Biology (11944)
- Cell Biology (17170)
- Clinical Trials (138)
- Developmental Biology (9307)
- Ecology (14022)
- Epidemiology (2067)
- Evolutionary Biology (18129)
- Genetics (12148)
- Genomics (16619)
- Immunology (11712)
- Microbiology (27702)
- Molecular Biology (11401)
- Neuroscience (60106)
- Paleontology (448)
- Pathology (1849)
- Pharmacology and Toxicology (3184)
- Physiology (4878)
- Plant Biology (10279)
- Synthetic Biology (2849)
- Systems Biology (7291)
- Zoology (1619)